CLINICAL TRIALS PROFILE FOR YASMIN
✉ Email this page to a colleague
All Clinical Trials for YASMIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00089414 ↗ | Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives | Terminated | National Institute of Mental Health (NIMH) | Phase 2 | 2004-07-01 | This study will determine whether uninterrupted treatment with birth control pills over several menstrual cycles prevents severe premenstrual syndrome (PMDD). Previous studies have shown that the hormones estrogen and progesterone regulate mood in women with MRMD. This study will use various treatment regimens with birth control pills and placebo (sugar pill) to clarify the relationships among estrogen and progesterone, the menstrual cycle, and mood. Healthy women between 18 and 45 years of age who menstruate may be eligible for this 15-week study. Candidates are screened with a physical examination, blood and urine tests, an electrocardiogram, and 3 months of symptoms ratings to confirm MRMD. Participants are randomly assigned to one of three treatment groups. Group 1 takes a birth control pill every day and on three occasions takes a placebo capsule. Group 2 takes a birth control pill most but not all days and on three occasions takes a placebo capsule. Group 3 takes a birth control pill every day and on three occasions takes another medication called CDB-2914 that causes menstrual bleeding to occur. Participants come to the NIH clinic every other week for blood tests and measurement of vital signs (blood pressure, pulse, and temperature) and to complete symptoms ratings scales. Subjects who develop breakthrough bleeding (menstruation earlier than expected) will have a transvaginal ultrasound. For this procedure, a probe is inserted into the vagina for about 10 minutes. The probe gives off and receives sound waves that can be used to form a picture of the endometrium (lining of the uterus). ... |
| NCT00185419 ↗ | A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception | Completed | Bayer | Phase 3 | 2003-11-01 | The purpose of this study is to evaluate the effectiveness in terms of prevention of pregnancy and safety of the oral contraceptive Yasmin and Marvelon on cycle control in healthy Chinese women |
| NCT00367276 ↗ | Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life. | Completed | Bayer | Phase 3 | 2002-12-01 | The purpose of this study is to evaluate the effects on the quality of life and BMI of new contraceptives. |
| NCT00413062 ↗ | Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2006-06-01 | The primary purpose of this study is to assess contraceptive efficacy, vaginal bleeding patterns (cycle control), general safety and acceptability of the nomegestrol acetate-estradiol (NOMAC-E2) combined oral contraceptive (COC) in a large group of women aged 18-50 years. |
| NCT00442689 ↗ | Metabolic Syndrome in PCOS: Precursors and Interventions | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | N/A | 2006-07-01 | The purpose of this study is to investigate the metabolic effects of anti-androgens and oral contraceptive pills (OCPs), compared with placebo, in the treatment of women with PCOS. We hypothesized that controlling elevated androgen levels with either anti-androgens or OCPs would produce improvement in metabolic markers in PCOS women and would reduce their long term metabolic risk. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for YASMIN
Condition Name
Clinical Trial Locations for YASMIN
Trials by Country
Clinical Trial Progress for YASMIN
Clinical Trial Phase
Clinical Trial Sponsors for YASMIN
Sponsor Name
